POPULARITY
In this episode, we dive into the early therapies and how our understanding of vascular physiology drastically changed the management of pulmonary hypertension. Intro 0:12 In this episode 0:18 Recap of part 1 & 2 0:31 What part 3 is about 2:31 WHO conference in 1975: Treating pulmonary hypertension 3:48 The Discovery of Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Part 1 5:20 Epoprostenol 6:18 Prostacyclin 10:37 Endothelin antagonists 11:41 Phosphodiesterase type 5 (PDE5) inhibitors 14:08 Interaction of nerves and blood vessels 15:06 The Soups VS the Sparks 17:36 A dreamed experiment 19:06 Acetylcholine 23:23 Enter “the calabar bean” 24:45 Acetylcholine and vasodilation: 1976 26:01 Rabbit aorta 27:45 Nitric oxide 29:38 Why are we using nitric oxide to treat pulmonary hypertension? 31:31 Tachyphylaxis 33:48 TNT factories 35:09 Nitrous oxide and tachyphylaxis 36:52 Pfizer in the 1980s 38:06 Understanding the trigger of pulmonary hypertension 40:53 PDE5 and nitric oxide and pulmonary hypertension 43:07 The end of the ripping yarns 44:20 Coming up in part 4 46:17 Thanks for listening 47:29 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bernard C. C R Soc Biol. 1851;3:163-164. Furchgott RF, et al. Nature. 1980;doi:10.1038/288373a0. Galiè N, et al. N Engl J Med. 2005;doi:10.1056/NEJMoa050010. Ghofrani HA, et al. Nat Rev Drug Discov. 2006;doi:10.1038/nrd2030. Giordano D, et al. Biochim Biophys Acta. 2001;doi:10.1016/s0167-4889(01)00086-6. Guthrie F. Q J Chem Soc. 1859;doi:10.1039/QJ8591100245. Higenbottam T, et al. Lancet. 1984;doi:10.1016/s0140-6736(84)91452-1. Marsh N, et al. Clin Exp Pharmacol Physiol. 2000;doi:10.1046/j.1440-1681.2000.03240.x. Montastruc JL, et al. Clin Auton Res. 1996;doi:10.1007/BF02281906. Nejad SH, et al. Future Cardiol. 2024;doi:10.1080/14796678.2024.2367390. Tansey EM. C R Biol. 2006;doi:10.10116/j.crvi.2006.03.012. Warren JV. Trans Am Clin Climatol Assoc. 1988;99:10-6. Disclosures: Brown reports no relevant financial disclosures.
A Rebelião Saudável nasceu da união de diversos profissionais de saúde que pensam diferente e cujo foco é promover saúde e bem estar, com comida de verdade e sem medicamentos. Semanalmente a Rebelião se reune no app Telegram para discussão de tópicos importantes relacionados a Nutrição Humana e Qualidade de vida. Nessa semana, a Rebelião discutiu sobre Manteiga X Margarina. Artigos citados no podcast: Ramsden CE, Zamora D, Leelarthaepin B, Majchrzak-Hong SF, Faurot KR, Suchindran CM, Ringel A, Davis JM, Hibbeln JR. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ. 2013 Feb 4;346:e8707. doi: 10.1136/bmj.e8707. Erratum in: BMJ. 2013;346:f903. PMID: 23386268; PMCID: PMC4688426. Khaw KT, Sharp SJ, Finikarides L, Afzal I, Lentjes M, Luben R, Forouhi NG. Randomised trial of coconut oil, olive oil or butter on blood lipids and other cardiovascular risk factors in healthy men and women. BMJ Open. 2018 Mar 6;8(3):e020167. doi: 10.1136/bmjopen-2017-020167. PMID: 29511019; PMCID: PMC5855206. Makhmudova U, Schulze PC, Lütjohann D, Weingärtner O. Phytosterols and Cardiovascular Disease. Curr Atheroscler Rep. 2021 Sep 1;23(11):68. doi: 10.1007/s11883-021-00964-x. PMID: 34468867; PMCID: PMC8410723. DiNicolantonio JJ, O'Keefe JH. Omega-6 vegetable oils as a driver of coronary heart disease: the oxidized linoleic acid hypothesis. Open Heart. 2018 Sep 26;5(2):e000898. doi: 10.1136/openhrt-2018-000898. PMID: 30364556; PMCID: PMC6196963. Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968-73). BMJ. 2016 Apr 12;353:i1246. doi: 10.1136/bmj.i1246. PMID: 27071971; PMCID: PMC4836695. Phytosterols may play role in atherosclerosis: https://www.ajmc.com/view/jun04-1804p3# Deol P, Evans JR, Dhahbi J, Chellappa K, Han DS, Spindler S, Sladek FM. Soybean Oil Is More Obesogenic and Diabetogenic than Coconut Oil and Fructose in Mouse: Potential Role for the Liver. PLoS One. 2015 Jul 22;10(7):e0132672. doi: 10.1371/journal.pone.0132672. PMID: 26200659; PMCID: PMC4511588. Dias CB, Wood LG, Garg ML. Effects of dietary saturated and n-6 polyunsaturated fatty acids on the incorporation of long-chain n-3 polyunsaturated fatty acids into blood lipids. Eur J Clin Nutr. 2016 Jul;70(7):812-8. doi: 10.1038/ejcn.2015.213. Epub 2016 Jan 13. PMID: 26757835. Spiteller G. Linoleic acid peroxidation--the dominant lipid peroxidation process in low density lipoprotein--and its relationship to chronic diseases. Chem Phys Lipids. 1998 Oct;95(2):105-62. doi: 10.1016/s0009-3084(98)00091-7. PMID: 9853364. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, Madsen L, Kristiansen K, Frøyland L, Hibbeln JR. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity (Silver Spring). 2012 Oct;20(10):1984-94. doi: 10.1038/oby.2012.38. Epub 2012 Feb 15. PMID: 22334255; PMCID: PMC3458187. Guyenet SJ, Carlson SE. Increase in adipose tissue linoleic acid of US adults in the last half century. Adv Nutr. 2015 Nov 13;6(6):660-4. doi: 10.3945/an.115.009944. PMID: 26567191; PMCID: PMC4642429. Penzo D, Tagliapietra C, Colonna R, Petronilli V, Bernardi P. Effects of fatty acids on mitochondria: implications for cell death. Biochim Biophys Acta. 2002 Sep 10;1555(1-3):160-5. doi: 10.1016/s0005-2728(02)00272-4. PMID: 12206909. Livros para Pesquisa: SHANAHAN, Catherine. The Fatburn Fix: boost energy, end hunger, and lose weight by using body fat for fuel. New York: Flat Iron Books, 2020. 352 p. TEICHOLZ, Nina. Gordura sem Medo: por que a manteiga, a carne e o queijo devem fazer parte de uma dieta saudável. São Paulo: Wmf Martins Fontes, 2020. 464 p. Você também pode nos acompanhar no instagram, http://www.instagram.com/henriqueautran.
Join FlightBridgeEDs new Chief Medical Director, Mike Lauria, as we launch the FlightBridgeED MDCast. Dr. Lauria will hijack these episodes for a new perspective on current topics in critical care medicine. In this episode, Dr. Lauria looks at Eric's previously published podcast [episode 224] on ASA Overdose and gives his insight, practical application, and overall thoughts on these difficult-to-manage patients. Don't miss this episode! So much good stuff! Please like, subscribe, and leave any questions or comments. References for Acute Salicylate Intoxication Anderson RJ, Potts DE, Gabow PA, Rumack BH, Schrier RW. Unrecognized adult salicylate intoxication. Ann Intern Med. Dec 1976;85(6):745-8. doi:10.7326/0003-4819-85-6-745 Chyka PA, Erdman AR, Christianson G, et al. Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(2):95-131. doi:10.1080/15563650600907140 Dargan PI, Wallace CI, Jones AL. An evidence-based flowchart to guide the management of acute salicylate (aspirin) overdose. Emerg Med J. May 2002;19(3):206-9. doi:10.1136/emj.19.3.206 Delaney TM, Helvey JT, Shiffermiller JF. A Case of Salicylate Toxicity Presenting with Acute Focal Neurologic Deficit in a 61-Year-Old Woman with a History of Stroke. Am J Case Rep. Feb 15 2020;21:e920016. doi:10.12659/AJCR.920016 Espírito Santo R, Vaz S, Jalles F, Boto L, Abecasis F. Salicylate Intoxication in an Infant: A Case Report. Drug Saf Case Rep. Nov 27 2017;4(1):23. doi:10.1007/s40800-017-0065-9 Goldberg MA, Barlow CF, Roth LJ. The effects of carbon dioxide on the entry and accumulation of drugs in the central nervous system. J Pharmacol Exp Ther. Mar 1961;131:308-18. Juurlink DN, Gosselin S, Kielstein JT, et al. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med. Aug 2015;66(2):165-81. doi:10.1016/j.annemergmed.2015.03.031 Kuzak N, Brubacher JR, Kennedy JR. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila). Jun-Aug 2007;45(5):526-9. doi:10.1080/15563650701365800 McCabe DJ, Lu JJ. The association of hemodialysis and survival in intubated salicylate-poisoned patients. Am J Emerg Med. Jun 2017;35(6):899-903. doi:10.1016/j.ajem.2017.04.017 Miyahara JT, Karler R. Effect of salicylate on oxidative phosphorylation and respiration of mitochondrial fragments. Biochem J. Oct 1965;97(1):194-8. doi:10.1042/bj0970194 Oliver TK, Jr., Dyer ME. The prompt treatment of salicylism with sodium bicarbonate. AMA J Dis Child. May 1960;99:553-65. doi:10.1001/archpedi.1960.02070030555001 Oualha M, Dupic L, Bastian C, Bergounioux J, Bodemer C, Lesage F. [Local salicylate transcutaneous absorption: an unrecognized risk of severe intoxication: a case report]. Arch Pediatr. Oct 2012;19(10):1089-92. Application cutanée localisée d'acide salicylique : un risque méconnu d'intoxication : à propos d'un cas. doi:10.1016/j.arcped.2012.07.012 Palmer BF, Clegg DJ. Salicylate Toxicity. N Engl J Med. Jun 25 2020;382(26):2544-2555. doi:10.1056/NEJMra2010852 Penniall R. The effects of salicylic acid on the respiratory activity of mitochondria. Biochim Biophys Acta. Nov 1958;30(2):247-51. doi:10.1016/0006-3002(58)90047-7 Shively RM, Hoffman RS, Manini AF. Acute salicylate poisoning: risk factors for severe outcome. Clin Toxicol (Phila). Mar 2017;55(3):175-180. doi:10.1080/15563650.2016.1271127 Stolbach AI, Hoffman RS, Nelson LS. Mechanical ventilation was associated with acidemia in a case series of salicylate-poisoned patients. Acad Emerg Med. Sep 2008;15(9):866-9. doi:10.1111/j.1553-2712.2008.00205.x Thurston JH, Pollock PG, Warren SK, Jones EM. Reduced brain glucose with normal plasma glucose in salicylate poisoning. J Clin Invest. Nov 1970;49(11):2139-45. doi:10.1172/JCI106431 See omnystudio.com/listener for privacy information.
References Circulation Research. 2008;102:283–294 Neurochemical Research volume 45, pages 972–988 (2020) Biochim Biophys Acta. 2008 Sep; 1781(9): 519–524. --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message
Episode 347 is an updated guide to somatropic hormone and GOD did I go crazy on this one! I honestly want to know more about growth hormone than anyone alive and thus, begins this string of GH based guides! I DID finally discuss the MoA for how GH causes localized fat loss which really had me excited since no one in our industry has EVER talked about this so that definitely was an interesting avenue to go down! Below I am going to reference a lot of the literature for this hormone that I was read through over the past few years on this topic so please DO NOT TAKE MY WORD FOR THIS - READ THESE YOURSELF! Keep in mind this is a brief snippet of every bit of literature on the topic however. REFERENCES Daughaday WH, Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev. 1989;10:68–91. [PubMed] [Google Scholar] Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34. [PubMed] [Google Scholar] Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22:53–74. [PubMed] [Google Scholar] Melmed S. Endocrinology. 5th edn. Philadelphia: Elsevier Saunders; 2006. pp. 411–428. [Google Scholar] Fain, J. N., García‐Sáinz, JA. (1983) Adrenergic regulation of adipocytes metabolism. J Lipid Res 24: 945– 966. CAS PubMed Web of Science®Google Scholar Gilman, AG. (1987) G protein: transducer of receptor‐generated signals. Annu Rev Biochem 56: 615– 649. Crossref CAS PubMed Web of Science®Google Scholar Jimenez, M., Lèger, B., Canola, K., et al (2002) Beta(1)/beta(2)/beta(3)‐adrenoceptor knockout mice are obese and cold‐sensitive but have normal lipolytic responses to fasting. FEBS Lett 530: 37– 40. Wiley Online Library CAS PubMed Web of Science®Google Scholar Birnbaumer, L., Abramowitz, J., Brown, AM. (1990) Receptor‐effector coupling by G proteins. Biochim Biophys Acta 1031: 163– 224. Crossref CAS PubMed Web of Science®Google Scholar Spiegel, A. M., Shenker, A., Weinstein, LS. (1992) Receptor‐effector coupling by G‐protein: implications for normal and abnormal signal transduction. Endocr Rev 13: 536– 565. Crossref CAS PubMed Web of Science®Google Scholar Beebe, S. J., Holloway, R., Rannels, R. S., Corbin, JD. (1984) Two classes of cAMP analogs which are selective for the two different cAMP‐binding sites of type II protein kinase demonstrate synergism when added together to intact adipocytes. J Biol Chem 269: 3539– 3547. PubMed Google Scholar Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48–58. [PubMed] [Google Scholar] Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science. 2003;299:1346–1351. [PubMed] [Google Scholar] Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res. 2004;14:261–269. [PubMed] [Google Scholar] Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab. 2003;14:28–34. [PubMed] [Google Scholar] Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928. [PubMed] [Google Scholar] Mayo KE. A little lesson in growth regulation. Nat Genet. 1996;12:8–9. [PubMed] [Google Scholar] Rosenfeld RG, Rosenbloom AL, Guevara-Aguirre J. Growth hormone (GH) insensitivity due to primary GH receptor deficiency. Endocr Rev. 1994;15:369–390. [PubMed] [Google Scholar] Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, Rundle AC, Wells JA, Carlsson LM. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med. 1995;333:1093–1098. [PubMed] [Google Scholar] Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, Kiess W, Klammt J, Kratzsch J, Osgood D, Pfaffle R, Raile K, Seidel B, Smith RJ, Chernausek SD. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med. 2003;349:2211–2222. [PubMed] [Google Scholar] Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med. 1996;335:1363–1367. [PubMed] [Google Scholar] Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol. 2001;229:141–162. [PubMed] [Google Scholar] Powell-Braxton L, Hollingshead P, Warburton C, Dowd M, Pitts-Meek S, Dalton D, Gillett N, Stewart TA. IGF-I is required for normal embryonic growth in mice. Genes Dev. 1993;7:2609–2617. [PubMed] [Google Scholar] Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, Pende M. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc Natl Acad Sci U S A. 2006;103:7315–7320. [PMC free article] [PubMed] [Google Scholar] Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D. Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest. 2002;109:347–355. [PMC free article] [PubMed] [Google Scholar] Coleman ME, DeMayo F, Yin KC, Lee HM, Geske R, Montgomery C, Schwartz RJ. Myogenic vector expression of insulin-like growth factor I stimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem. 1995;270:12109–12116. [PubMed] [Google Scholar] Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney HL. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci U S A. 1998;95:15603–15607. [PMC free article] [PubMed] [Google Scholar] Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC, Glass DJ, Yancopoulos GD. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014–1019. [PubMed] [Google Scholar] Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, Rosenthal N. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001;27:195–200. [PubMed] [Google Scholar] Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol. 2002;157:137– 148. [PMC free article] [PubMed] [Google Scholar] Caroni P, Schneider C. Signaling by insulin-like growth factors in paralyzed skeletal muscle: rapid induction of IGF1 expression in muscle fibers and prevention of interstitial cell proliferation by IGF-BP5 and IGF-BP4. J Neurosci. 1994;14:3378–3388. [PMC free article] [PubMed] [Google Scholar] Edwall D, Schalling M, Jennische E, Norstedt G. Induction of insulin-like growth factor I messenger ribonucleic acid during regeneration of rat skeletal muscle. Endocrinology. 1989;124:820–825. [PubMed] [Google Scholar] DeVol DL, Rotwein P, Sadow JL, Novakofski J, Bechtel PJ. Activation of insulin-like growth factor gene expression during work-induced skeletal muscle growth. Am J Physiol. 1990;259:E89–E95. [PubMed] [Google Scholar] Carson JA, Nettleton D, Reecy JM. Differential gene expression in the rat soleus muscle during early work overload-induced hypertrophy. FASEB J. 2002;16:207–209. [PubMed] [Google Scholar] Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol. 2006;36:1–7. [PubMed] [Google Scholar] Herrington J, Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001;12:252–257. [PubMed] [Google Scholar] Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006;7:225–235. [PubMed] [Google Scholar] Rotwein P, Thomas MJ, Harris DM, Gronowski AM, LeStunff C. Nuclear actions of growth hormone: an in vivo perspective. J Anim Sci. 1997;75:11–19. [Google Scholar] Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene. 2000;19:2585–2597. [PubMed] [Google Scholar] Levy DE, Darnell JEJ. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol. 2002;3:651–662. [PubMed] [Google Scholar] Gronowski AM, Rotwein P. Rapid changes in nuclear protein tyrosine phosphorylation after growth hormone treatment in vivo. Identification of phosphorylated mitogen-activated protein kinase and STAT91. J Biol Chem. 1994;269:7874–7878. [PubMed] [Google Scholar] Gronowski AM, Zhong Z, Wen Z, Thomas MJ, Darnell JEJ, Rotwein P. In vivo growth hormone treatment rapidly stimulates the tyrosine phosphorylation and activation of Stat3. Mol Endocrinol. 1995;9:171–177. [PubMed] [Google Scholar] Ram PA, Park SH, Choi HK, Waxman DJ. Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J Biol Chem. 1996;271:5929–5940. [PubMed] [Google Scholar] Campbell GS, Meyer DJ, Raz R, Levy DE, Schwartz J, Carter-Su C. Activation of acute phase response factor (APRF)/Stat3 transcription factor by growth hormone. J Biol Chem. 1995;270:3974–3979. [PubMed] [Google Scholar] Smit LS, Vanderkuur JA, Stimage A, Han Y, Luo G, Yu-Lee LY, Schwartz J, Carter-Su C. Growth hormone-induced tyrosyl phosphorylation and deoxyribonucleic acid binding activity of Stat5A and Stat5B. Endocrinology. 1997;138:3426–3434. [PubMed] [Google Scholar] Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, Carter-Su C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol. 1996;10:519–533. [PubMed] [Google Scholar] Gebert CA, Park SH, Waxman DJ. Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol Endocrinol. 1997;11:400–414. [PubMed] [Google Scholar] Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, Brown M, Bodner S, Grosveld G, Ihle JN. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841–850. [PubMed] [Google Scholar] Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A. 1997;94:7239–7244. [PMC free article] [PubMed] [Google Scholar] Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodnik L, Jasper H, Tepper A, Heinrich JJ, Rosenfeld RG. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med. 2003;349:1139–1147. [PubMed] [Google Scholar] Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, Berberoglu M, Rosenfeld RG. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab. 2005;90:4260–4266. [PubMed] [Google Scholar] Rosenfeld RG, Belgorosky A, Camacho-Hubner C, Savage MO, Wit JM, Hwa V. Defects in growth hormone receptor signaling. Trends Endocrinol Metab. 2007;18:134–141. [PubMed] [Google Scholar] Thompson BJ, Shang CA, Waters MJ. Identification of genes induced by growth hormone in rat liver using cDNA arrays. Endocrinology. 2000;141:4321–4324. [PubMed] [Google Scholar] Flores-Morales A, Stahlberg N, Tollet-Egnell P, Lundeberg J, Malek RL, Quackenbush J, Lee NH, Norstedt G. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology. 2001;142:3163–3176. [PubMed] [Google Scholar] Rowland JE, Lichanska AM, Kerr LM, White M, d'Aniello EM, Maher SL, Brown R, Teasdale RD, Noakes PG, Waters MJ. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol. 2005;25:66–77. [PMC free article] [PubMed] [Google Scholar] Huo JS, McEachin RC, Cui TX, Duggal NK, Hai T, States DJ, Schwartz J. Profiles of growth hormone (GH)-regulated genes reveal time-dependent responses and identify a mechanism for regulation of activating transcription factor 3 by GH. J Biol Chem. 2006;281:4132–4141. [PubMed] [Google Scholar] Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, Woelfle J, Ono M, Lenhard B, Norstedt G, Rotwein P, Flores-Morales A. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol. 2007;21:293–311. [PubMed] [Google Scholar] Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol. 2006;20:1333–1351. [PubMed] [Google Scholar] Jorgensen JO, Jessen N, Pedersen SB, Vestergaard E, Gormsen L, Lund SA, Billestrup N. GH receptor signaling in skeletal muscle and adipose tissue in human subjects following exposure to an intravenous GH bolus. Am J Physiol Endocrinol Metab. 2006;291:E899–E905. [PubMed] [Google Scholar] Nielsen C, Gormsen LC, Jessen N, Pedersen SB, Moller N, Lund S, Jorgensen JO. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J Clin Endocrinol Metab. 2008;93:2842–2850. [PubMed] [Google Scholar] Waxman DJ, O'Connor C. Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol. 2006;20:2613–2629. [PubMed] [Google Scholar] Wauthier V, Waxman DJ. Sex-specific early growth hormone response genes in rat liver. Mol Endocrinol. 2008;22:1962–1974. [PMC free article] [PubMed] [Google Scholar] Ahluwalia A, Clodfelter KH, Waxman DJ. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. Mol Endocrinol. 2004;18:747–760. [PubMed] [Google Scholar] Zhou YC, Waxman DJ. Cross-talk between janus kinase-signal transducer and activator of transcription (JAK-STAT) and peroxisome proliferator-activated receptor-alpha (PPARalpha) signaling pathways. Growth hormone inhibition of pparalpha transcriptional activity mediated by stat5b. J Biol Chem. 1999;274:2672–2681. [PubMed] [Google Scholar] Zhou YC, Waxman DJ. STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 transactivation domain. J Biol Chem. 1999;274:29874–29882. [PubMed] [Google Scholar] Ono M, Chia DJ, Merino-Martinez R, Flores-Morales A, Unterman TG, Rotwein P. Signal transducer and activator of transcription (Stat) 5b-mediated inhibition of insulin-like growth factor binding protein-1 gene transcription: a mechanism for repression of gene expression by growth hormone. Mol Endocrinol. 2007;21:1443–1457. [PubMed] [Google Scholar] Murphy LJ. Insulin-like growth factor-binding proteins: functional diversity or redundancy? J Mol Endocrinol. 1998;21:97–107. [PubMed] [Google Scholar] Barthel A, Schmoll D, Unterman TG. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab. 2005;16:183–189. [PubMed] [Google Scholar] Accili D, Arden KC. FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell. 2004;117:421–426. [PubMed] [Google Scholar] Rotwein P. Contemporary endocrinology: the IGF system. Totowa: Humana Press; 1999. Molecular biology of IGF-I and IGF-II; pp. 19–35. [Google Scholar] Hall LJ, Kajimoto Y, Bichell D, Kim SW, James PL, Counts D, Nixon LJ, Tobin G, Rotwein P. Functional analysis of the rat insulin-like growth factor I gene and identification of an IGF-I gene promoter. DNA Cell Biol. 1992;11:301–313. [PubMed] [Google Scholar] Adamo ML, Ben-Hur H, Roberts CTJ, LeRoith D. Regulation of start site usage in the leader exons of the rat insulin-like growth factor-I gene by development, fasting, and diabetes. Mol Endocrinol. 1991;5:1677–1686. [PubMed] [Google Scholar] Shimatsu A, Rotwein P. Mosaic evolution of the insulin-like growth factors. Organization, sequence, and expression of the rat insulin-like growth factor I gene. J Biol Chem. 1987;262:7894–7900. [PubMed] [Google Scholar] Kim SW, Lajara R, Rotwein P. Structure and function of a human insulin-like growth factor-I gene promoter. Mol Endocrinol. 1991;5:1964–1972. [PubMed] [Google Scholar] Kavsan VM, Koval AP, Grebenjuk VA, Chan SJ, Steiner DF, Roberts CTJ, LeRoith D. Structure of the chum salmon insulin-like growth factor I gene. DNA Cell Biol. 1993;12:729–737. [PubMed] [Google Scholar] Hoyt EC, Van Wyk JJ, Lund PK. Tissue and development specific regulation of a complex family of rat insulin-like growth factor I messenger ribonucleic acids. Mol Endocrinol. 1988;2:1077–1086. [PubMed] [Google Scholar] Woelfle J, Billiard J, Rotwein P. Acute control of insulin-like growth factor-1 gene transcription by growth hormone through STAT5B. J Biol Chem. 2003;278:22696–22702. [PubMed] [Google Scholar] Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action. Identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003;278:51261–51266. [PubMed] [Google Scholar] Bichell DP, Kikuchi K, Rotwein P. Growth hormone rapidly activates insulin-like growth factor I gene transcription in vivo. Mol Endocrinol. 1992;6:1899–1908. [PubMed] [Google Scholar] Thomas MJ, Kikuchi K, Bichell DP, Rotwein P. Characterization of deoxyribonucleic acid-protein interactions at a growth hormone-inducible nuclease hypersensitive site in the rat insulin-like growth factor-I gene. Endocrinology. 1995;136:562–569. [PubMed] [Google Scholar] An MR, Lowe WLJ. The major promoter of the rat insulin-like growth factor-I gene binds a protein complex that is required for basal expression. Mol Cell Endocrinol. 1995;114:77–89. [PubMed] [Google Scholar] Mittanck DW, Kim SW, Rotwein P. Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol. 1997;126:153–163. [PubMed] [Google Scholar] Wang L,Wang X, Adamo ML. Two putative GATA motifs in the proximal exon 1 promoter of the rat insulin-like growth factor I gene regulate basal promoter activity. Endocrinology. 2000;141:1118–1126. [PubMed] [Google Scholar] Wang X, Talamantez JL, Adamo ML. A CACCC box in the proximal exon 2 promoter of the rat insulin-like growth factor I gene is required for basal promoter activity. Endocrinology. 1998;139:1054–1066. [PubMed] [Google Scholar] Wang Y, Jiang H. Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem. 2005;280:10955–10963. [PubMed] [Google Scholar] Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H, Rotwein P. Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-I gene transcription. J Biol Chem. 2006;281:3190–3197. [PubMed] [Google Scholar] Eleswarapu S, Gu Z, Jiang H. Growth hormone regulation of insulin-like growth factor-I gene expression may be mediated by multiple distal signal transducer and activator of transcription 5 binding sites. Endocrinology. 2008;149:2230–2240. [PMC free article] [PubMed] [Google Scholar] Björntorp, P. (1992) Biochemistry of obesity in relation to diabetes. In: KGMM Alberti RA DeFronzo H Keen P Zimmet eds. International Textbook of Diabetes Mellitus 551– 568. John Wiley & Sons Ltd London, United Kingdom. Google Scholar Björntorp, P. (1992) Hormonal effects on fat distribution and its relationship to health risk factors. Acta Paediatr Suppl 383: 59– 60. CAS PubMed Google Scholar Rosèn, T., Bosaeus, I., Tolli, J., Lindstedt, G., Bengtsson, BA. (1993) Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 38: 63 Wiley Online Library PubMed Web of Science®Google Scholar Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r) Cell. 1993;75:59–72. [PubMed] [Google Scholar] Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, Okada S, Cataldo L, Coschigamo K, Wagner TE, Baumann G, Kopchick JJ. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse) Proc Natl Acad Sci U S A. 1997;94:13215–13220. [PMC free article] [PubMed] [Google Scholar] Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest. 2000;106:1095–1103. [PMC free article] [PubMed] [Google Scholar] Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771–781. [PMC free article] [PubMed] [Google Scholar] Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology. 2001;142:4349–4356. [PubMed] [Google Scholar] Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. [PubMed] [Google Scholar] Ishizuya T, Yokose S, Hori M, Noda T, Suda T, Yoshiki S, Yamaguchi A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest. 1997;99:2961–2970. [PMC free article] [PubMed] [Google Scholar] McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology. 1989;124:1247–1253. [PubMed] [Google Scholar] Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141:2674–2682. [PubMed] [Google Scholar] Bengtsson, BÅ, Edén, S., Lönn, L., et al (1993) Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76: 309– 317. Crossref CAS PubMed Web of Science®Google Scholar Al‐Shoumer, K. A. S., Page, B., Thomas, E., Murphy, M., Beshyah, S. A., Johnston, DG. (1996) Effects of four years’ treatment with biosynthetic human growth hormone (GH) on body composition in GH‐deficient hypopituitary adults. Eur Endocrinol 135: 559– 567. Crossref CAS PubMed Web of Science®Google Scholar Li, C. H., Simpson, M. E., Evans, HM. (1949) Influence of growth and adrenocorticotropic hormone on the body composition of hypophysectomized rats. Endocrinology 44: 71– 75. Crossref CAS PubMed Web of Science®Google Scholar Scow, RO. (1959) Effects of growth hormone and thyroxine on growth and chemical composition of muscle, bone and other tissues in thyroidectomized‐hypophysectomized rats. Am J Physiol 196: 859– 865. CAS PubMed Web of Science®Google Scholar Lee, M. O., Schaffer, NK. (1934) Anterior pituitary growth hormone and the composition of growth. J Nutr 7: 337– 363. Crossref CAS Web of Science®Google Scholar Goodman, H. M., Schwartz, J. (1974) Growth hormone and lipid metabolism. In: E Enobil WH Sawyer eds. Handbook of Physiology, Part 2 IV: 211– 232. American Physiological Society Washington DC. Google Scholar Bengtsson, BÅ, Brummer, R. J. M., Edén, S., Rosèn, T., Sjöström, L. (1992) Effects of growth hormone on fat mass and fat distribution. Acta Paediatr Suppl 383: 62– 65. PubMed Google Scholar Tanner, J. M., Hughes, P. C. R., Whitehouse, RH. (1977) Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency. Acta Endocrinol (Copenh) 84: 53– 57. Google Scholar Goodman, H. M., Gorin, E., Honeyman, TW. (1988) Biochemical basis for the lipolytic activity of growth hormone. In: LE Underwood eds. Human Growth Hormone: Progress and Challenges 75– 111. Marcel Dekker Inc New York. Google Scholar Bonnet, F., Vanderschueren‐Lodeweyckx, M., Echels, R., Malvaux, P. (1974) Subcutaneous adipose tissue and lipids in blood in growth hormone deficiency before and after treatment with human growth hormone. Pediatr Res 8: 800– 805. Crossref CAS PubMed Web of Science®Google Scholar van Vliet, G, Bosson, D., Craen, M., Caju, NVLD, Malvaux, P., Vanderschueren‐Lodeweyckx, M. (1987) Comparative study of the lipolytic potencies of pituitary‐derived and biosynthetic human growth hormone in hypopituitary children. J Clin Endocrinol Metab 65: 876– 879. Crossref PubMed Web of Science®Google Scholar Beauville, M., Harent, I., Crampes, F., Riviere, D., Tauber, M. T., Tauber, J. P., Garrigues, M. (1992) Effect of long‐term rhGH administration in GH‐deficient adults on fat cell epinephrine response. Am J Physiol 263: E467– E472. Crossref CAS PubMed Web of Science®Google Scholar Vernon, R. G., Flint, DJ. (1989) Role of growth hormone in the regulation of adipocyte growth and function. In: RB Heap, C Prosser GE Lamming eds. Biotechnology in Growth Regulation 57– 71. Butterworths London, United Kingdom. Crossref Web of Science®Google Scholar Harant, I., Beauville, M., Crampes, F., et al (1994) Response of fat cells to growth hormone (GH): effect of long term treatment with recombinant human GH in GH‐deficient adults. J Clin Endocrinol Metab 78: 1392– 1395. Crossref PubMed Web of Science®Google Scholar Marcus, C., Bolme, P., Micha‐Johansson, G., Margery, V., Brönnegård, M. (1994) Growth hormone increases the lipolytic sensitivity from catecholamines in adipocytes from healthy adults. Life Sci 54: 1335– 1341. Crossref CAS PubMed Web of Science®Google Scholar Yang, S., Björntorp, P., Liu, X., Edén, S. (1996) Growth hormone treatment of hypophysectomized rats increases catecholamine‐induced lipolysis and the number of β‐adrenergic receptors in adipocytes: no differences in the effects of growth hormone on different fat depots. Obes Res 4: 471– 478. Wiley Online Library CAS PubMed Web of Science®Google Scholar Watt, P. W., Finley, E., Cork, S., Legg, R. A., Vernon, RG. (1991) Chronic control of the β‐ and α2‐adrenergic systems of sheep adipose tissue by growth hormone and insulin. Biochem J 273: 39– 42. Crossref CAS PubMed Web of Science®Google Scholar Arner, P. (1992) Adrenergic receptor function in fat cells. Am J Clin Nutr 55: 228S– 236S. Crossref CAS PubMed Web of Science®Google Scholar Arner, P., Hellmér, J., Wennlund, A., Östman, J., Engfeldt, P. (1988) Adrenoceptor occupancy in isolated human fat cells and its relationship with lipolysis rate. Eur J Pharmacol 146: 45– 56. Crossref CAS PubMed Web of Science®Google Scholar Davidson, MB. (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8: 115– 131. Crossref CAS PubMed Web of Science®Google Scholar Ottosson, M., Lönnroth, P., Björntorp, Edén S. (2000) Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinol Metab 85: 799– 803. Crossref CAS PubMed Web of Science®Google Scholar Pierlussi, J., Pierlussi, R., Aschcroft, SJH. (1980) Effects of growth hormone on insulin release in the rat. Diabetologia 19: 391– 396. Crossref PubMed Web of Science®Google Scholar Roupas, P., Ghou, S. T., Towns, R. J., Kostyo, JL. (1991) Growth hormone inhibits activation of phosphatidylinositol phospholipase C in adipose plasma membranes: evidence for a growth hormone‐induced change in G protein function. Physiol Pharmacol 88: 1691– 1695. CAS PubMed Web of Science®Google Scholar 72 Slavin, B. G., Ong, J. M., Kern, P. (1994) Hormonal regulation of hormone‐sensitive lipase activity and mRNA levels in isolated rat adiposities. J Lipid Res 35: 1535– 1541. CAS PubMed Web of Science®Google Scholar Sheridan, MK. (1986) Effects of thyroxin, cortisol, growth hormone, and prolactin on lipid metabolism of coho salmon, oncorhynchus kisutch, during smoltification. Gen Comp Endocrinol 64: 220– 238. Crossref CAS PubMed Web of Science®Google Scholar Dietz, J., Schwartz, J. (1991) Microdetermination of long chain fatty acids in plasma and tissue. J Biol Chem 235: 2595– 2599. PubMed Web of Science®Google Scholar Yang, S., Xu, X., Björntorp, P., Edén, S. (1995) Additive effects of growth hormone and testosterone on lipolysis in adipocytes of hypophysectomized rats. J Endocrinol 147: 147– 152. Crossref CAS PubMed Web of Science®Google Scholar Lands, A. M., Arnold, A., McAuliff, J. P., Bron, TG. (1967) Differentiation of receptor systems activated by sympathetic amines. Nature 214: 597– 598. Crossref CAS PubMed Web of Science®Google Scholar Stiles, G. L., Caron, M. G., Lefkowitz, RJ. (1984) β‐Adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev 64: 661– 743. Crossref CAS PubMed Web of Science®Google Scholar Emorine, L. J., Marullo, S., Briend‐Sutren, M. M., et al (1989) Molecular characterization of human β3‐adrenergic receptor. Science 245: 1118– 1121. Crossref CAS PubMed Web of Science®Google Scholar Ahquist, RP. (1948) A study of the adrenotropic receptors. Am J Physiol 153: 586– 600. PubMed Web of Science®Google Scholar Honnor, R. C., Dhillon, G. S., Londos, C. (1985) cAMP‐dependent protein kinase and lipolysis in rat adipocytes. I. Cell preparation, manipulation and predictability in behavior. J Biol Chem 260: 15122– 15129. CAS PubMed Web of Science®Google Scholar Honnor, R. C., Dhillon, G. S., Londos, C. (1985) cAMP‐dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady‐state relationship with lipolytic and antilipolytic modulators. J Biol Chem 260: 15130– 15138. CAS PubMed Web of Science®Google Scholar Corbin, J. D., Cobb, C. E., Beebe, S. J., et al (1988) Mechanism and function of cAMP‐ and cGMP‐dependent protein kinases. Adv Second Messenger Phosphoprotein Res 21: 75– 86. CAS PubMed Web of Science®Google Scholar Londos, C., Brasaemle, D. L., Schultz, C. J., Segrest, J. P., Kimmel, AR. (1999) Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin Cell Dev Biol 10: 51– 58. Crossref CAS PubMed Web of Science®Google Scholar Holm, C., Osterlund, T., Laurell, H., Contreras, JA. (2000) Molecular mechanisms regulating hormone‐sensitive lipase and lipolysis. Annu Rev Nutr 20: 365– 393. Crossref CAS PubMed Web of Science®Google Scholar Brasaemle, D. L., Rubin, B., Harten, I. A., Gruia‐Gray, J., Kimmel, A. R., Londos, C. (2000) Perilipin A increases triacylglycerol storage by decreasing the rate of triacylglycerol hydrolysis. J Biol Chem 275: 38486– 38493. Crossref CAS PubMed Web of Science®Google Scholar Tansey, J. T., Huml, A. M., Vogt, R., et al (2003) Functional studies on native and mutated forms of perilipins. A role in protein kinase A‐mediated lipolysis of triacylglycerols. J Biol Chem 278: 8401– 8406. Crossref CAS PubMed Web of Science®Google Scholar Strålfors, P., Björgell, P., Belfrage, P. (1984) Hormone regulation of hormone‐sensitive lipase in intact adipocytes: Identification of phosphorylated sites and effects of the phosphorylation by lipolytic hormone and insulin. Proc Natl Acad Sci U S A 81: 3317– 3321. Crossref CAS PubMed Web of Science®Google Scholar Egan, J. J., Greenberg, A. S., Chang, M. K., Wek, SA Moos JMC, Londos, C. (1992) Mechanism of hormone‐stimulated lipolysis in adipocytes: translocation of hormone‐sensitive lipase to the lipid storage droplet. Proc Natl Acad Sci U S A 89: 8537– 8541. Crossref CAS PubMed Web of Science®Google Scholar Anthonsen, M. W., Ronnstrand, L., Wernstedt, C., Degerman, E., Holm, C. (1998) Identification of novel phosphorylation sites in hormone‐sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro. J Biol Chem 273: 215– 221. Crossref CAS PubMed Web of Science®Google Scholar Sztalryd, C., Xu, G., Dorward, H., et al (2003) Perilipin A is essential for the translocation of hormone‐sensitive lipase during lipolytic activation. J Cell Boil 161: 1093– 1103. Crossref CAS PubMed Web of Science®Google Scholar Smith, PE. (1930) Hypophysectomy and replacement therapy in the rat. Am J Anat 45: 205– 273. Wiley Online Library Web of Science®Google Scholar Edén, S., Jansson, J. O., Oscarsson, J. (1987) Sexual dimorphism of growth hormone secretion. In: O Isaksson C Binder K Hall B Hökfelt eds. Growth Hormone—Basic and Clinical Aspects 129– 151. Elsevier Science Publishers B.V Amsterdam. Google Scholar Frohman, L. A., Bernardis, LL. (1970) Growth hormone secretion in rat: metabolic clearance and secretion rates. Endocrinology 86: 305– 312. Crossref CAS PubMed Google Scholar Jansson, J. O., Albertsson‐Wikaland, K., Edén, S., Thorngren, K. G., Isaksson, O. (1982) Circumstantial evidence for a role of the secretory pattern of growth hormone in control of body growth. Acta Endocrinol 99: 24– 30. CAS PubMed Web of Science®Google Scholar Björntorp, P., Karlsson, M., Pertoft, H., Pettersson, P., Sjöström, L., Smith, U. (1978) Isolation and characterization of cells from rat adipose tissue developing into adipocytes. J Lipid Res 19: 316– 324. CAS PubMed Web of Science®Google Scholar Lowry, O. H., Rosebrough, N. J., Farr, A. L., Randall, RJ. (1951) Protein measurements with the folin phenol reagent. J Biol Chem 193: 265– 275. CAS PubMed Web of Science®Google Scholar Rebuffé‐Scrive, M. (1987) Sex steroid hormones and adipose tissue metabolism in adrenalectomized and ovariectomized rats. Acta Physiol Scand 129: 471– 477. Wiley Online Library CAS PubMed Web of Science®Google Scholar Laurell, S., Tibbling, G. (1966) An enzymatic fluorometric micromethod for the determination of glycerol. Clin Chim Acta 13: 317– 322. Crossref CAS PubMed Web of Science®Google Scholar Dole, V. P., Meinertz, H. (1960) Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235: 2595– 2599. CAS PubMed Web of Science®Google Scholar Smith, U., Sjöström, L., Björntorp, P. (1972) Comparison of two methods of determining human adipose cell size. J Lipid Res 13: 822– 824. CAS PubMed Web of Science®Google Scholar Östman, J., Arner, P., Kimura, H., Wahrenberg, H., Engfeldt, P. (1984) Influence of fasting on lipolytic response to adrenergic agonists and on adrenergic receptors in subcutaneous adipocytes. Eur J Clin Invest 14: 383– 391. Wiley Online Library PubMed Web of Science®Google Scholar Steiner, A. L., Pagliara, A. S., Chase, L. R., Kipnis, DM. (1972) Radioimmunoassay for cyclic nucleotides. II. Adenosine 3′, 5′‐monophosphate and guanosine 3′, 5′‐monophosphate in mammalian tissues and body fluids. J Biol Chem 247: 1114– 1120. CAS PubMed Web of Science®Google Scholar Steiner, A. L., Parker, C. W., Kipnis, DM. (1972) Radioimmunoassay for cyclic nucleotides. I. Preparation of antibodies and iodinated cyclic nucleotides. J Biol Chem 247: 1106– 1113. CAS PubMed Web of Science®Google Scholar McKenzie, FR. (1988) Basic techniques to study G‐protein function. In: G Milligan eds. Signal Transduction—A Practical Approach, Part 2 31– 56. Oxford University Press New York. Google Scholar Solomon, S. S., Sibley, S. D., Dismukes, J.R. (1991) Growth hormone‐enhanced lipolysis in the spontaneously diabetic BB rat. J Lab Clin Med 118: 99– 105. CAS PubMed Web of Science®Google Scholar Nam, S. Y., Marcus, C. (2000) Growth hormone and adipocyte function in obesity. Horm Res 53: (Suppl 1), 87– 97. Crossref CAS PubMed Web of Science®Google Scholar Bahouth, S. W., Malbon, CC. (1988) Subclassification of β‐adrenergic receptors of rat fat cells: a re‐evaluation. Mol Pharmacol 34: 318– 326. CAS PubMed Web of Science®Google Scholar Granneman, J. G., Lahners, K. N., Chaudhry, A. (1992) Molecular cloning and expression of the rat β3‐adrenergic receptor. Mol Pharmacol 40: 895– 899. Web of Science®Google Scholar Hollenga, C. H., Zaagsma, J. (1989) Direct evidence for the atypical nature of functional β‐adrenoceptors in rat adipocytes. Br J Pharmacol 98: 1420– 1424. Wiley Online Library CAS PubMed Web of Science®Google Scholar Lacasa, D., Agli, B., Giudicelli, Y. (1985) Direct assessment of β‐adrenergic receptors in intact rat adipocytes by binding of [3H]CGP 12177. Eur J Biochem 146: 339– 346. Wiley Online Library CAS PubMed Web of Science®Google Scholar Umekawa, T., Yoshida, T., Sakane, N., Kondo, M. (1996) Effect of CL316, 243, a highly specific β3‐adrenoceptor agonit, on lipolysis of human and rat adipocytes. Horm Metab Res 28: 394– 396. Crossref CAS PubMed Web of Science®Google Scholar Bojanic, D., Nahorski, SR. (1983) Identification and subclassification of rat adipocyte β‐adrenoceptors using (±)‐[125I]cyanopindolol. Eur J Pharmacol 93: 235– 243. Crossref CAS PubMed Web of Science®Google Scholar Langin, D., Portillo, M., Saulnier‐Blache, J. S., Lafontan, M. (1991) Coexistence of three beta‐adrenergic receptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol 199: 291– 301. Crossref CAS PubMed Web of Science®Google Scholar •••WANT YOUR QUESTION ANSWERED?••• Create a free account at www.theprepcoachforum.com and post up your question in the Mike Arnold PED Q&A open threat! •••SUPPORT OUR PEPTIDE/RESEARCH CHEMS SPONSORS••• (RESEARCH CHEMS) www.maresearchchems.net___use discount code “alex15” to save off your order! (SPECIALTY SUPPS) www.masupps.com___use discount code “alex20” to save off your order! (BEEF) www.skinnybeef.com___use discount code “alex10” to save off your order! •••FIND THE EPISODES••• ITUNES:https://itunes.apple.com/us/podcast/beastfitness-radios-podcast/id1065532968 LIBSYN:http://beastfitnessradio.libsyn.com VIMEO: www.vimeo.com/theprepcoach •••PREP COACH APPAREL••• https://teespring.com/stores/the-prep-coach-apparel
Support this podcast! https://anchor.fm/chubbyemu/support Video version of this podcast: https://www.youtube.com/watch?v=bxGS07U-B98 Video by Chubbyemu: A Farmer Removed His Own Skin Cancer With A Pocket Knife. This Is What Happened To His Brain. https://www.youtube.com/watch?v=KKaJhQBusH8 References: - Melanoma brain metastases: current areas of investigation and future directions. Cancer J. 2017 Jan-Feb; 23(1): 68–74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5300745/ - The metastatic cycle: metastatic niches and cancer cell dissemination. J Dtsch Dermatol Ges. 2014 Nov;12(11):1012-9. https://www.ncbi.nlm.nih.gov/pubmed/25307562 - BRAF Targets in Melanoma: Biological Mechanisms, Resistance, and Drug Discovery. Humana Press. 2015. - Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature2002;417:949-954. https://www.ncbi.nlm.nih.gov/pubmed/12068308?dopt=Abstract - MAP kinase pathways: the first twenty years. Biochim Biophys Acta. 2007 Aug;1773(8):1150-60. Epub 2006 Nov 15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043147/ Music by Lifeformed. Please check out his music at his Bandcamp: https://lifeformed.bandcamp.com --- Support this podcast: https://anchor.fm/chubbyemu/support
References:Adriana Sarah Nica, Adela Caramoci, Mirela Vasilescu, Anca Mirela Ionescu, Denis Paduraru, Virgil Mazilu. Magnesium supplementation in top athletes - effects and recommendations. Medicina Sportiva (2015), vol. XI, no 1, 2482-2494 Journal of the Romanian Sports Medicine SocietyAikawa JW. Magnesium: its biological significance. Boca Raton, FL: CRC Press, 1981:21–38.Abbasi B, Kimiagar M, Sadeghnijat K, Shirazi MM, Hedayati M, Rashidkhani B. “The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial.” J Res Med Sci. 2012 Dec 17 (12): 1161-9.PubMed PMID: 23853635. Arnaud MJ: Update on the assessment of magnesium status. Br J Nutr 2008;99(suppl 3):S24–S36 Brilla LR, Haley TF. Effect of magnesium supplementation on strength training in humans. J Am Coll Nutr 1992;11:326Chandrasekaran NC, Weir C, Alfraji S, Grice J, Roberts MS, Barnard RT. Effects of magnesium deficiency--more than skin deep. Exp Biol Med (Maywood). 2014 Oct;239(10):1280-91. doi: 10.1177/1535370214537745. Epub 2014 Jun 13.Ebel H, Gunther T. Magnesium metabolism: a review. J Clin Chem Biochem 1980;18:257–70.Emelyanov A, Fedoseev G, Barnes PJ: Re- duced intracellular magnesium concentra- tions in asthmatic patients. Eur Respir J 1999;13:38–40.Fawcett WJ, Haxby EJ, Male DA: Magnesium: physiology and pharmacology. Br J Anaesth 1999;83:302–320.Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1997.Guerrero-Romero F, Rodríguez-Morán M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord. 2002;26:469–74.Hosty´nek JJ, Hinz RS, Lorence CR, Price M, Guy RH. Metals and the skin. Crit Rev Toxicol 1993;23:171–235Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012;5:i3–i14Kupetsky-Rincon EA1, Uitto J. Magnesium: novel applications in cardiovascular disease--a review of the literature. Ann Nutr Metb. 2012;61(2):102-10.Lansdown AB. Physiological and toxicological changes in the skin resulting from the action and interaction of metal ions. Crit Rev Toxicol1995;25:397–462.Mochizuki M, Akagi K, Inoue K, Shimamura K.[A single dose toxicity study of magnesium sulfate in rats and dogs]. J Toxicol Sci. 1998 May;23 Suppl 1:31-5Navarrete-Cortes A, Ble-Castillo JL, Guerrero-Romero F, Cordova-Uscanga R, Juárez-Rojop IE, Aguilar-Mariscal H, Tovilla-Zarate CA, Lopez-Guevara Mdel R. No effect of magnesium supplementation on metabolic control and insulin sensitivity in type 2 diabetic patients with normomagnesemia. Magnes Res. 2014 Apr-Jun;27(2):48-56. doi: 10.1684/mrh.2014.0361.Nedeltcheva AV, Kilkus JM, Imperial J, Schoeller DA, Peney PD. “Insufficient sleep undermines dietary efforts to reduce adiposity.” ANN Intern Med. 2010 Oct 5:153(7):435-41. PubMed PMID: 20921542.Nowacki W, Daveau M, Malpuech-Bruge C. Inflammatory responsefollowing acute magnesium deficiency in the rat. Biochim Biophys Acta 2000;1501:91–8Nielsen FH, Johnson LK, Zeng H. Magnesium supplementation improves indicators of low magnesium status and inflammatory stress in adults older than 51 years with poor quality sleep. Magnes Res. 2010 Dec;23(4):158-68. doi: 10.1684/mrh.2010.0220. Epub 2011 Jan 4.Malon A, Brockmann C, Fijalkowska- Morawska J, Rob P, Maj-Zurawska M: Ionized magnesium in erythrocytes – the best magnesium parameter to observe hypo- or hypermagnesemia. Clin Chim Acta 2004; 349:67–73.Martin K, Jackson CF, Levy RG, Cooper PN. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016 Feb 9;2:CD001903. doi: 10.1002/14651858.CD001903.pub3.Meolie AL, Rosen C, Kristo D, Kohrman M, Gooneratne N, Aguillard RN, Fayle R, Troell R, Townsend D, Claman D, Hoban T, Mahowald M. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence; Clinical Practice Review Committee; American Academy of Sleep Medicine.J Clin Sleep Med. 2005 Apr 15;1(2):173-87.Rodríguez-Morán M, Guerrero-Romero F. Serum magnesium and C-reactive protein levels. Arch Dis Child. 2008;93:676–80University of Maryland Medical Center “Magnesium” access May 8. 2016 http://umm.edu/ health/medical/altmed/supplement/magnesiumShils ME. Magnesium. In: Shils ME, Olson JA, Shike M, eds. Modern nutrition in health and disease. 8th ed. Philadelphia: Lea & Febiger, 1993:164–84.Simsek E, Karabay M, Kocabay K: Assess- ment of magnesium status in newly diag- nosed diabetic children: measurement of erythrocyte magnesium level and magne- sium tolerance testing. Turk J Pediatr 2005; 47:132–137.Waring, RH Report on Absorption of magnesium sulfate (Epsom salts) across the skin. School of Biosciences, University of Birmingham. B15 2TT, U.K. r.h.waring@bham.ac.uk URL http://www.epsomsaltcouncil.org/wpcontent/uploads/2015/10/report_on_absorption_of_magnesium_sulfate.pdfWinkelmann RK. The relationship of the structure of the epidermis to percutaneous absorption. Br J Dermatol 1969;81:11–22Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnes Res. 2011 Dec;24(4):163-80. doi: 10.1684/mrh.2011.0292.
Episode 278 is an all inclusive guide to kidney anatomy, health, bloodwork, and MORE for physique and performance based athletes! First I dig into some basics on kidney anatomy and function before moving into some considerations for athletes looking to get bloodwork done to track kidney health, and all before ending with practical application on how to maintain kidney health while pushing for your goals! Also, theres a few references I'll provide below for those looking to take things further! REFERENCES Adelstein RS, Sellers JR. Effects of calcium on vascular smooth muscle contraction. The American journal of cardiology. Jan 30 1987;59(3):4b-10b. Agre P, King LS, Yasui M, Guggino WB, Ottersen OP, Fujiyoshi Y, . . . Nielsen S. Aquaporin water channels--from atomic structure to clinical medicine. The Journal of physiology. Jul 1 2002;542(Pt 1):3-16. AHA. American Heart Association. Kidney Damage and High Blood Pressure. Available at: http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/WhyBloodPressureMatters/Kidney-Damage-and-High-Blood-Pressure_UCM_301825_Article.jsp. Last updated 9/11/2014a. Accessed 8/10/2014. Akinwusi PO, Oluyombo R, Ogunro PS, Adeniji AO, Okunola OO, Ayodele OE. Low dose aspirin therapy and renal function in elderly patients. International journal of general medicine. 2013;6:19-24. Al-Awqati Q, Barasch J, Goldman L (ed.), SchaferAI (ed.). Goldman's Cecil Medicine, Twenty-Fourth Edition. Chapter 117: Structure and Function of the Kidneys; 716-720. Copyright 2012 Saunders, an imprint of Elsevier, Inc. Available at: www.clinicalkey.com Accessed: 6/9/2014. Alpern RJ, Sakhaee K. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. American journal of kidney diseases : the official journal of the National Kidney Foundation. Feb 1997;29(2):291-302. Amodu A, Abramowitz MK. Dietary acid, age, and serum bicarbonate levels among adults in the United States. Clinical journal of the American Society of Nephrology : CJASN. Dec 2013;8(12):2034-2042. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney international. Jun 2013;83(6):1010-1016. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, and Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. 2003;52(8):2110–20 Bae EH, Lee J, Ma SK, et al. alpha-Lipoic acid prevents cisplatin-induced acute kidney injury in rats. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2009;24(9):2692–700 Balakumar P, Bishnoi HK, Mahadevan N. Telmisartan in the management of diabetic nephropathy: a contemporary view. Current diabetes reviews. May 2012;8(3):183-190. Balakumar P, Rohilla A, Krishan P, Solairaj P, and Thangathirupathi A. The multifaceted therapeutic potential of benfotiamine. Pharmacol. Res. 2010;61(6):482–8 Bankir L, Bouby N, Trinh-Trang-Tan MM, Ahloulay M, Promeneur D. Direct and indirect cost of urea excretion. Kidney international. Jun 1996;49(6):1598-1607. Barbagallo M, Dominguez LJ, Galioto A, Pineo A, Belvedere M. Oral magnesium supplementation improves vascular function in elderly diabetic patients. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Sep 2010;23(3):131-137. Bashir B, Sharma SG, Stein HD, Sirota RA, D'Agati VD. Acute kidney injury secondary to exposure to insecticides used for bedbug (Cimex lectularis) control. American journal of kidney diseases : the official journal of the National Kidney Foundation. Nov 2013;62(5):974-977. Baynes JW, Dominiczak MH. Medical Biochemistry, Fourth Edition. Chapter 23: Role of Kidneys in Metabolism; 309-319. Copyright 2014, Elsevier Limited. Available at: www.clinicalkey.com. Accessed 6/9/2014. Bellizzi V. Low-protein diet or nutritional therapy in chronic kidney disease? Blood purification. 2013;36(1):41–6 Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical care (London, England). Aug 2004;8(4):R204-212. Bertelli AAE, Migliori M, Panichi V. Resveratrol, a component of wine and grapes, in the prevention of kidney disease. Ann N Y Acad Sci. 2002;957:230–8 Brodin EE, Braekkan SK, Vik A, Brox J, Hansen JB. Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromso study. Haematologica. Jul 2012;97(7):1008-1013. Busch M, Franke S, Ruster C, and Wolf G. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010;40(8):742–55 Cacciapuoti F. Lowering homocysteine levels may prevent cardiovascular impairments? Possible therapeutic behaviors. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. Dec 2012;23(8):677-679. Calhoun DA. Hyperaldosteronism as a common cause of resistant hypertension. Annu. Rev. Med. 2013;64:233–47 Ceglia L, Harris SS, Abrams SA, Rasmussen HM, Dallal GE, Dawson-Hughes B. Potassium bicarbonate attenuates the urinary nitrogen excretion that accompanies an increase in dietary protein and may promote calcium absorption. The Journal of clinical endocrinology and metabolism. Feb 2009;94(2):645-653. Chao MC, Hu SL, Hsu HS, Davidson LE, Lin CH, Li CI, . . . Lin WY. Serum homocysteine level is positively associated with chronic kidney disease in a Taiwan Chinese population. Journal of nephrology. Jan 16 2014. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biological trace element research. May 2010;134(2):119-129. Chen J, Muntner P, Hamm LL, et al. The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults. Ann Intern Med. 2004;140(3):167–74 Chen Y, Abbate M, Tang L. L-Carnitine supplementation for adults with end-stage kidney disease requiring maintenance hemodialysis: a systematic review and meta-analysis. American Journal of Clinical Nutrition. 2014;99(2):408–22 Cheungpasitporn W, Thongprayoon C, OA OC, Edmonds PJ, Kittanamongkolchai W, Erickson SB. Associations of Sugar and Artificially Sweetened Soda and Chronic Kidney Disease: A Systematic Review and Meta-analysis. Nephrology (Carlton, Vic.). Sep 23 2014. Chrysohoou C, Panagiotakos DB, Pitsavos C, Skoumas J, Zeimbekis A, Kastorini CM, Stefanadis C. Adherence to the Mediterranean diet is associated with renal function among healthy adults: the ATTICA study. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. May 2010;20(3):176-184. Cohen D, Goldberg M, Gulati A, and Ferri FF. First Consult. Chronic kidney disease. Available at: www.clinicalkey.com. Last updated 5/5/2010. Accessed 6/12/2014. 2010; Available at: [Accessed August 3, 2014]. Cravedi P, Remuzzi G. Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease. Br J Clin Pharmacol. 2013;76(4):516–23 Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clinical Kidney Journal. 2012;5(Suppl 1):i39-i51. Curiel RV, Katz JD. Mitigating the cardiovascular and renal effects of NSAIDs. Pain Med. 2013;14 Suppl 1:S23–8 Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review. Food Funct. 2012;3(12):1251–64 Davis KE, Prasad C, Vijayagopal P, Juma S, Imrhan V. Advanced Glycation End Products, Inflammation, and Chronic Metabolic Diseases:Links in a Chain? Critical reviews in food science and nutrition. Sep 26 2014. De la Fuente M, Hernanz A, Viniegra S, Miquel J. Sulfur-containing antioxidants increase in vitro several functions of lymphocytes from mice. International immunopharmacology. Jun 2011;11(6):661-669. Debreceni B, Debreceni L. The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease. Cardiovascular therapeutics. Jun 2014;32(3):130-138. Dempsher J. The nerve impulse in the axon--a new theory. Acta biotheoretica. 1981;30(2):121-137. Di Vito R, Sirolli V, Amoroso L, Bonomini M. [Nephrotoxicity induced by chemotherapy]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. May-Jun 2011;28(3):296-304. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes care. Sep 2011;34(9):2116-2122. Downie WW. Prostaglandins and NSAID in the kidney. The Journal of rheumatology. Supplement. Mar 1991;28:19-21. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A. Normal and pathologic concentrations of uremic toxins. Journal of the American Society of Nephrology : JASN. Jul 2012;23(7):1258-1270. Eknoyan G. Obesity and chronic kidney disease. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2011;31(4):397-403. Eknoyan G, Latos DL, Lindberg J, National Kidney Foundation Carnitine Consensus Conference. Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003;41(4):868–76. Faloon W. FDA Approves Deadly Drugs, Delays Lifesaving Therapies. Life Extension Magazine. http://www.lef.org//Magazine/2004/5/awsi/Page-01. May 2004. Accessed 1/26/2015. Feng B, Yan X-F, Xue J-L, Xu L, and Wang H. The Protective Effects of α-Lipoic Acid on Kidneys in Type 2 Diabetic Goto-Kakisaki Rats via Reducing Oxidative Stress. Int J Mol Sci. 2013;14(4):6746–56 Fenton TR, Tough SC, Lyon AW, Eliasziw M, Hanley DA. Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality. Nutrition journal. 2011;10:41. Ferri FF. Ferri's Clinical Advisor. Chronic Kidney Disease. Available at: www.clinicalkey.com. Copyright © 2014c. Accessed 6/12/2014. Ferri FF. Ferri's Clinical Advisor. Acute Kidney Injury. Available at: www.clinicalkey.com. Copyright © 2014a. Accessed 6/12/2014. Ferri FF. Ferri's Clinical Advisor. Polycystic Kidney Disease. Available at: www.clinicalkey.com. Copyright © 2014b. Accessed 6/12/2014. Finkielstein VA, Goldfarb DS. Strategies for preventing calcium oxalate stones. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. May 9 2006;174(10):1407-1409. Fjellstedt E, Denneberg T, Jeppsson JO, Tiselius HG. A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urological research. Oct 2001;29(5):295-302. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. American journal of kidney diseases : the official journal of the National Kidney Foundation. Jan 2001;37(1):79-83. Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. Journal of the American Society of Nephrology : JASN. Aug 2003;14(8 Suppl 3):S254-258. Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Archives of internal medicine. Apr 14 2008;168(7):713-720. Gaedeke J, Fels LM, Bokemeyer C, Mengs U, Stolte H, Lentzen H. Cisplatin nephrotoxicity and protection by silibinin. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Jan 1996;11(1):55-62. Gazdíková K, Gvozdjáková A, Kucharská J, Spustová V, Braunová Z, and Dzúrik R. Oxidative stress and plasma concentrations of coenzyme Q10, alpha-tocopherol, and beta-carotene in patients with a mild to moderate decrease of kidney function. Nephron. 2001;88(3):285 Geleijnse JM, Giltay EJ, Grobbee DE, Donders ART, and Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J. Hypertens. 2002;20(8):1493–9 Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antialdosterone properties. Climacteric : the journal of the International Menopause Society. Feb 2007;10 Suppl 1:11-18. GHR. Genetics Home Reference. Conditions page. Renal tubular dysgenesis. Available at: http://ghr.nlm.nih.gov/condition/renal-tubular-dysgenesis. 1/5/2015. Accessed 1/6/2015. 2015. Goraya N, Simoni J, Jo C, Wesson DE. Dietary acid reduction with fruits and vegetables or bicarbonate attenuates kidney injury in patients with a moderately reduced glomerular filtration rate due to hypertensive nephropathy. Kidney international. Jan 2012;81(1):86-93. Goraya N, Wesson DE. Dietary management of chronic kidney disease: protein restriction and beyond. Current opinion in nephrology and hypertension. Nov 2012;21(6):635-640. Goraya N, Wesson DE. Does correction of metabolic acidosis slow chronic kidney disease progression? Current opinion in nephrology and hypertension. Mar 2013;22(2):193-197. Gowda S, Desai PB, Kulkarni SS, Hull VV, Math AA, Vernekar SN. Markers of renal function tests. North American journal of medical sciences. Apr 2010;2(4):170-173. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Pirulli A, Barazzoni R. Metabolic syndrome and chronic kidney disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. Sep 2010;20(5 Suppl):S19-23. Gupta A, Biyani M, and Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med. 2011;69(9):379–83 Hall ME, do Carmo JM, da Silva AA, Juncos LA, Wang Z, Hall JE. Obesity, hypertension, and chronic kidney disease. International journal of nephrology and renovascular disease. 2014;7:75-88. Hamilton KL, Butt AG. The molecular basis of renal tubular transport disorders. Comparative biochemistry and physiology. Part A, Molecular & integrative physiology. Jul 2000;126(3):305-321. Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion. The American journal of physiology. Oct 1987;253(4 Pt 2):F595-605. Hanly L, Rieder MJ, Huang SH, Vasylyeva TL, Shah RK, Regueira O, Koren G. N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique. 2013;20(2):e132-145. Harisa GI. Benfotiamine enhances antioxidant defenses and protects against cisplatin-induced DNA damage in nephrotoxic rats. J. Biochem. Mol. Toxicol. 2013;27(8):398–405 Hartweg J, Farmer AJ, Holman RR, and Neil HAW. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 2007;50(2):250–8 Hataya Y, Igarashi S, Yamashita T, and Komatsu Y. Thyroid hormone replacement therapy for primary hypothyroidism leads to significant improvement of renal function in chronic kidney disease patients. Clinical and experimental nephrology. 2013;17(4):525–31 Hawley MA. The Kidney Transplant/Dialysis Association Patient Handbook. Chapter 1: Normal and Abnormal Kidney Function. Available at: http://msl1.mit.edu/ESD10/kidneys/HndbkHTML/ch1.htm. Accessed 1/6/2015. 2015. Hazard PB, Griffin JP. Calculation of sodium bicarbonate requirement in metabolic acidosis. The American journal of the medical sciences. Jan-Feb 1982;283(1):18-22. Heidet L, Gubler M-C. The renal lesions of Alport syndrome. J. Am. Soc. Nephrol. 2009;20(6):1210–5 Ho MJ, Bellusci A, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2009;(4):CD007435 Hodgson JM, Watts GF, Playford DA, Burke V, and Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56(11):1137–42 Hojs R, Bevc S, Antolinc B, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in the elderly. International journal of clinical pharmacology research. 2004;24(2-3):49-54. Holthoff JH, Wang Z, Seely KA, Gokden N, and Mayeux PR. Resveratrol improves renal microcirculation, protects the tubular epithelium, and prolongs survival in a mouse model of sepsis-induced acute kidney injury. Kidney Int. 2012;81(4):370–8 Houston M. The role of magnesium in hypertension and cardiovascular disease. Journal of clinical hypertension (Greenwich, Conn.). Nov 2011;13(11):843-847. Kanda E, Ai M, Yoshida M, Kuriyama R, Shiigai T. High serum bicarbonate level within the normal range prevents the progression of chronic kidney disease in elderly chronic kidney disease patients. BMC nephrology. 2013;14:4. Karachalias N, Babaei-Jadidi R, Rabbani N, and Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. 2010;53(7):1506–16 Karalius VP, Shoham DA. Dietary sugar and artificial sweetener intake and chronic kidney disease: a review. Advances in chronic kidney disease. 2013;20(2):157–64 Karimi G, Ramezani M, Tahoonian Z. Cisplatin nephrotoxicity and protection by milk thistle extract in rats. Evidence-based complementary and alternative medicine : eCAM. Sep 2005;2(3):383-386. Karsai T, Elodi P. Urea cycle enzymes in human liver: ontogenesis and interaction with the synthesis of pyrimidines and polyamines. Molecular and cellular biochemistry. 1982;43(2):105-110. Kaur J. A comprehensive review on metabolic syndrome. Cardiology research and practice. 2014;2014:943162. Kaysen GA. Albumin turnover in renal disease. Mineral and electrolyte metabolism. 1998;24(1):55-63. Khalifeh N, Haider D, Horl WH. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. Jan 2009;57(1):33-39. Khan SA, Priyamvada S, Khan W, Khan S, Farooq N, and Yusufi ANK. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol. Res. 2009;60(5):382–91 Kihm LP, Müller-Krebs S, Klein J. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J. Am. Soc. Nephrol. 2011;22(5):914–26 Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. Journal of the American Society of Nephrology : JASN. Jul 2005;16(7):2134-2140. Kurtz TW. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta diabetologica. Apr 2005;42 Suppl 1:S9-16. LaCivita C, Funkhouser E, Miller MJ, Ray MN, Saag KG, Kiefe CI, . . . Allison JJ. Patient-reported communications with pharmacy staff at community pharmacies: the Alabama NSAID Patient Safety Study, 2005-2007. Journal of the American Pharmacists Association : JAPhA. Sep-Oct 2009;49(5):e110-117. Lacour B, Parry C, Drüeke T, et al. Pyridoxal 5'-phosphate deficiency in uremic undialyzed, hemodialyzed, and non-uremic kidney transplant patients. Clin. Chim. Acta. 1983;127(2):205–15 Lahoti TS, Patel D, Thekkemadom V, Beckett R, Ray SD. Doxorubicin-induced in vivo nephrotoxicity involves oxidative stress-mediated multiple pro- and anti-apoptotic signaling pathways. Current neurovascular research. Nov 2012;9(4):282-295. Lameire N, Kruse V, Rottey S. Nephrotoxicity of anticancer drugs--an underestimated problem? Acta clinica Belgica. 2011;66(5):337–45 Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012;17(2):251–61 Latchoumycandane C, Nagy LE, McIntyre TM. Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation. Free radical biology & medicine. Apr 2014;69:403-416. Launay-Vacher V, Rey JB, Isnard-Bagins C, et al. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008;61(6):903-9. Laville M, Nazare JA. Diabetes, insulin resistance and sugars. Obesity reviews : an official journal of the International Association for the Study of Obesity. Mar 2009;10 Suppl 1:24-33. Le Vaillant J, Pellerin L, Brouard J, Eckart P. [Acetaminophen (paracetamol) causing renal failure: report on 3 pediatric cases]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie. Jun 2013;20(6):650-653. Lee JT, Peng GS, Chen SY, Hsu CH, Lin CC, Cheng CA, . . . Lin JC. Homocysteine induces cerebral endothelial cell death by activating the acid sphingomyelinase ceramide pathway. Progress in neuro-psychopharmacology & biological psychiatry. Aug 1 2013;45:21-27. Leslie RD, Cohen RM. Biologic variability in plasma glucose, hemoglobin A1c, and advanced glycation end products associated with diabetes complications. Journal of diabetes science and technology. Jul 2009;3(4):635-643. Leu J-G, Lin C-Y, Jian J-H, Shih C-Y, and Liang Y-J. Epigallocatechin-3-gallate combined with alpha lipoic acid attenuates high glucose-induced receptor for advanced glycation end products (RAGE) expression in human embryonic kidney cells. An. Acad. Bras. Cienc. 2013;85(2):745–52 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of internal medicine. Mar 16 1999;130(6):461-470. Li H, Weatherford ET, Davis DR, Keen HL, Grobe JL, Daugherty A, . . . Sigmund CD. Renal proximal tubule angiotensin AT1A receptors regulate blood pressure. American journal of physiology. Regulatory, integrative and comparative physiology. Oct 2011;301(4):R1067-1077. Li G, Gao L, Jia J, Gong X, Zang B, and Chen W. α-Lipoic acid prolongs survival and attenuates acute kidney injury in a rat model of sepsis. Clin. Exp. Pharmacol. Physiol. 2014;41(7):459–68 Lin J, Fung TT, Hu FB, Curhan GC. Association of dietary patterns with albuminuria and kidney function decline in older white women: a subgroup analysis from the Nurses' Health Study. American journal of kidney diseases : the official journal of the National Kidney Foundation. Feb 2011;57(2):245-254. Lin J, Judd S, Le A, et al. Associations of dietary fat with albuminuria and kidney dysfunction. American Journal of Clinical Nutrition. 2010;92(4):897–904 Linden E, Cai W, He JC, Xue C, Li Z, Winston J, . . . Uribarri J. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clinical journal of the American Society of Nephrology : CJASN. May 2008;3(3):691-698. Liu H, Peng Y, Li J, Liu Y, Cheng M, Yuan F, Liu F. [Stages of 3,547 patients with chronic kidney disease and relevant factor analysis]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences. May 2010;35(5):499-510. Lyman JL. Blood urea nitrogen and creatinine. Emergency medicine clinics of North America. May 1986;4(2):223-233. Machado V, Cabral A, Monteiro P, et al. Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin). Rev Port Cardiol. 2008;27(10):1277-96. Magill SB. Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. Comprehensive Physiology. Jul 2014;4(3):1083-1119. Malarkodi KP, Balachandar AV, Sivaprasad R, and Varalakshmi P. Prophylactic effect of lipoic acid against adriamycin-induced peroxidative damages in rat kidney. Ren Fail. 2003;25(3):367–77 Mandayam S, Mitch WE. Dietary protein restriction benefits patients with chronic kidney disease. Nephrology (Carlton, Vic.). Feb 2006;11(1):53-57. Mariani LH, White MT, Shults J, et al. Increasing use of vitamin D supplementation in the chronic renal insufficiency cohort study. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2014;24(3):186–93 Marnett LJ, Rowlinson SW, Goodwin DC, Kalgutkar AS, Lanzo CA. Arachidonic Acid Oxygenation by COX-1 and COX-2: MECHANISMS OF CATALYSIS AND INHIBITION. Journal of Biological Chemistry. August 13, 1999 1999;274(33):22903-22906. Marre M, Garcia Puig J, Kokot F, Fernandez M, Jermendy G, Opie L, . . . Asmar R. Effect of indapamide SR on microalbuminuria--the NESTOR study (Natrilix SR versus Enalapril Study in Type 2 diabetic hypertensives with micrOalbuminuRia)--rationale and protocol for the main trial. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. Mar 2003;21(1):S19-24. McCarron DA. Dietary sodium and cardiovascular and renal disease risk factors: dark horse or phantom entry? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. Jul 2008;23(7):2133-2137. MedicineNet. Metabolic Syndrome: How is metabolic syndrome defined? Available at: http://www.medicinenet.com/metabolic_syndrome/article.htm#how_is_metabolic_syndrome_defined. 9/19/2014. Accessed 9/19/2014. Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes care. Jul 2009;32(7):1320-1326. Mekki K, Bouzidi-bekada N, Kaddous A, Bouchenak M. Mediterranean diet improves dyslipidemia and biomarkers in chronic renal failure patients. Food & function. Oct 2010;1(1):110-115. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, . . . Sarnak MJ. Cystatin C as a risk factor for outcomes in chronic kidney disease. Annals of internal medicine. Jul 3 2007;147(1):19-27. Meola M, Petrucci I. [Ultrasound and color Doppler in nephrology. Acute kidney injury]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. Sep-Oct 2012;29(5):599-615. Meyer BR. Renal function in aging. Journal of the American Geriatrics Society. Aug 1989;37(8):791-800. Michael A, Faga T, Pisani A, and Riccio E. Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast media. 2014;2014:249810 Minich DM, Bland JS. Acid-alkaline balance: role in chronic disease and detoxification. Alternative therapies in health and medicine. Jul-Aug 2007;13(4):62-65. Mirmiran P, Shab-Bidar S, Hosseini-Esfahani F, Asghari G, Hosseinpour-Niazi S, Azizi F. Magnesium intake and prevalence of metabolic syndrome in adults: Tehran Lipid and Glucose Study. Public health nutrition. Apr 2012;15(4):693-701. Mithieux G, Andreelli F, Magnan C. Intestinal gluconeogenesis: key signal of central control of energy and glucose homeostasis. Current opinion in clinical nutrition and metabolic care. Jul 2009;12(4):419-423. Mithieux G, Misery P, Magnan C, Pillot B, Gautier-Stein A, Bernard C, . . . Zitoun C. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab. Nov 2005;2(5):321-329. Mithieux G. A novel function of intestinal gluconeogenesis: central signaling in glucose and energy homeostasis. Nutrition (Burbank, Los Angeles County, Calif.). Sep 2009;25(9):881-884. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clinical journal of the American Society of Nephrology : CJASN. Feb 2010;5(2):299-306. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, . . . Kovesdy CP. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. Journal of the American College of Cardiology. Feb 25 2014;63(7):650-658. Montemurno E, Cosola C, Dalfino G, Daidone G, De Angelis M, Gobbetti M, Gesualdo L. What Would You Like to Eat, Mr CKD Microbiota? A Mediterranean Diet, please! Kidney & blood pressure research. Jul 29 2014;39(2-3):114-123. Mori TA, Burke V, Puddey I, et al. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial. J. Hypertens. 2009;27(9):1863–72 Mountokalakis TD. Magnesium metabolism in chronic renal failure. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. Jun 1990;3(2):121-127. Munekage E, Takezaki Y, Hanazaki K. [Shortage and metabolic disturbance of magnesium in diabetic patients and significance of magnesium replacement therapy]. Clinical calcium. Aug 2012;22(8):1235-1242. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annual review of pharmacology and toxicology. 1993;33:435-465. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney international. Apr 2002;61(4):1453-1461. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease. European journal of clinical investigation. Sep 2010;40(9):790-796. Nakamura S, Li H, Adijiang A, Pischetsrieder M, and Niwa T. Pyridoxal phosphate prevents progression of diabetic nephropathy. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2007;22(8):2165–74 Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes, metabolic syndrome and obesity : targets and therapy. 2014;7:421-435. Navar LG. The kidney in blood pressure regulation and development of hypertension. The Medical clinics of North America. Sep 1997;81(5):1165-1198. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Family practice. Jun 2013;30(3):247-255. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney international. Jan 1995;47(1):312-318. NHGRI. National Human Genome Research Institute. Health page. Learning About Autosomal Dominant Polycystic Kidney Disease. Last updated 4/18/2013. Accessed 1/6/2015. NIH. National Institutes of Health. MedlinePlus. Kidney Disease: Early Detection and Treatment. Available at: http://www.nlm.nih.gov/medlineplus/magazine/issues/winter08/articles/winter08pg9-10.html. Copyright 2008. Accessed 9/19/2014. NKDEP. National Kidney Disease Education Program. Laboratory Evaluation page. Reporting GFR. Available at: http://nkdep.nih.gov/lab-evaluation/gfr/reporting.shtml. Last updated 6/6/2012. Accessed 10/21/2014. NKF. National Kidney Foundation. About Chronic Kidney Disease. Available at: http://www.kidney.org/kidneydisease/aboutckd. Copyright 2013a. Accessed 9/19/2014. NKF. National Kidney Foundation. Acute Kidney Injury. Available at: http://www.kidney.org/news/kidneyCare/fall10/AcuteKidneyInjury. Copyright 2013b. Accessed 9/19/2014. NKF. National Kidney Foundation. Statement on the release of ibuprofen as an over-the-counter medicine. Ad Hoc Committee for the National Kidney Foundation. American journal of kidney diseases : the official journal of the National Kidney Foundation. Jul 1985;6(1):4-6. Patrick L. Mercury toxicity and antioxidants: Part 1: role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002;7(6):456–71 Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, . . . Pugliese G. HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes care. Aug 2013;36(8):2301-2310. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. The New England journal of medicine. Dec 22 1994;331(25):1675-1679. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integrative cancer therapies. Jun 2007;6(2):104-109. Pozzi C, Marai P, Ponti R, Dell'Oro C, Sala C, Zedda S, Locatelli F. Toxicity in man due to stain removers containing 1,2-dichloropropane. British journal of industrial medicine. Nov 1985;42(11):770-772. Prieto J, Qian C, Garcia N, Diez J, Medina JF. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology. Aug 1993;105(2):572-578. PubMed Health. DASH Eating Plan. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0063068/. Last updated 6/11/2014. Accessed 10/21/2014. Pushpakumar SB, Kundu S, Sen U. Endothelial dysfunction: The link between homocysteine and hydrogen sulfide. Current medicinal chemistry. Jul 6 2014. Qin J, Wang H, Rets A, Harari S, Alexis H, Eid I, Pincus MR. Stability of BUN and creatinine determinations on the Siemens Advia 1800 analyzer. Journal of clinical laboratory analysis. Nov 2013;27(6):435-437. Quigley R. Chronic kidney disease: highlights for the general pediatrician. International journal of pediatrics. 2012;2012:943904. Radbill B, Murphy B, LeRoith D. Rationale and strategies for early detection and management of diabetic kidney disease. Mayo Clinic proceedings. Dec 2008;83(12):1373-1381. Sabolić I. Common mechanisms in nephropathy induced by toxic metals. Nephron Physiol. 2006;104(3):p107–14 Saddadi F, Alatab S, Pasha F, Ganji MR, Soleimanian T. The effect of treatment with N-acetylcysteine on the serum levels of C-reactive protein and interleukin-6 in patients on hemodialysis. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. Jan 2014;25(1):66-72. Sahin K, Tuzcu M, Gencoglu H, et al. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci. 2010;87(7-8):240–5 Saifan C, Samarneh M, Shtaynberg N, Nasr R, El-Charabaty E, and El-Sayegh S. Treatment of confirmed B12 deficiency in hemodialysis patients improves Epogen® requirements. Int J Nephrol Renovasc Dis. 2013;6:89–93 Saldanha JF, Leal Vde O, Stenvinkel P, Carraro-Eduardo JC, and Mafra D. Resveratrol: why is it a promising therapy for chronic kidney disease patients? Oxid Med Cell Longev. 2013;2013:963217 Salerno MP, Piselli P, Rossi E, Favi E, Gargiulo A, Spagnoletti G, . . . Citterio F. Metabolic syndrome and cardiovascular disease in kidney transplantation. Transplantation proceedings. May 2011;43(4):1067-1068. Salgado JV, Souza FL, Salgado BJ. How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? Journal of cardiology. Dec 2013;62(6):331-335. Samuni Y, Goldstein S, Dean OM, and Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013;1830(8):4117–29 Scialla JJ, Appel LJ, Astor BC, Miller ER, 3rd, Beddhu S, Woodward M, . . . Anderson CA. Estimated net endogenous acid production and serum bicarbonate in African Americans with chronic kidney disease. Clinical journal of the American Society of Nephrology : CJASN. Jul 2011;6(7):1526-1532. Segal R, Lubart E, Leibovitz A, Iaina A, Caspi D. Renal effects of low dose aspirin in elderly patients. The Israel Medical Association journal : IMAJ. Oct 2006;8(10):679-682. Seifter JL. Acid-base disorders. Chapter 120. Pages 741-753. In: Goldman’s Cecil Medicine. Published 12/31/2011. Available at: www.clinicalkey.com. Accessed 10/21/2014. Sener G, Sehirli O, Ipci Y, Cetinel S, Cikler E, Gedik N, Alican I. Protective effects of taurine against nicotine-induced oxidative damage of rat urinary bladder and kidney. Pharmacology. Apr 2005;74(1):37-44. Senturk H, Kabay S, Bayramoglu G, et al. Silymarin attenuates the renal ischemia/reperfusion injury-induced morphological changes in the rat kidney. World J Urol. 2008;26(4):401–7 Shepler B, Nash C, Smith C, Dimarco A, Petty J, and Szewciw S. Update on potential drugs for the treatment of diabetic kidney disease. Clin Ther. 2012;34(6):1237–46 Shin BC, Kwon YE, Chung JH, and Kim HL. The antiproteinuric effects of green tea extract on acute cyclosporine-induced nephrotoxicity in rats. Transplant. Proc. 2012;44(4):1080–2 Shin DH, Lee MJ, Kim SJ, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2012;97(8):2732–40 Shishehbor MH, Oliveira LP, Lauer MS, Sprecher DL, Wolski K, Cho L, . . . Hazen SL. Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease. The American journal of cardiology. Jun 15 2008;101(12):1741-1746. Shlipak MG, Matsushita K, Arnlov J, Inker LA, Katz R, Polkinghorne KR, . . . Gansevoort RT. Cystatin C versus creatinine in determining risk based on kidney function. The New England journal of medicine. Sep 5 2013;369(10):932-943. Shlipak MG, Mattes MD, Peralta CA. Update on cystatin C: incorporation into clinical practice. American journal of kidney diseases : the official journal of the National Kidney Foundation. Sep 2013;62(3):595-603. Soto C, Pérez J, García V, Uría E, Vadillo M, and Raya L. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 2010;17(14):1090–4 Soulage CO, Koppe L, Fouque D. Protein-bound uremic toxins...new targets to prevent insulin resistance and dysmetabolism in patients with chronic kidney disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. Nov 2013;23(6):464-466. Stanton RC. Clinical challenges in diagnosis and management of diabetic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. Feb 2014;63(2 Suppl 2):S3-21. Starke A, Corsenca A, Kohler T, Knubben J, Kraenzlin M, Uebelhart D, . . . Ambuhl PM. Correction of metabolic acidosis with potassium citrate in renal transplant patients and its effect on bone quality. Clinical journal of the American Society of Nephrology : CJASN. Sep 2012;7(9):1461-1472. Szczepańska-Konkel M, Dominiczak MH, JW B. Medical Biochemistry, Fourth Edition. Chapter 23: Role of Kidneys in Metabolism; 309-319. Copyright 2014, Elsevier Limited. Available at: www.clinicalkey.com Accessed 6/9/2014. Tang PC, Ng YF, Ho S, Gyda M, Chan SW. Resveratrol and cardiovascular health - Promising therapeutic or hopeless illusion? Pharmacological research : the official journal of the Italian Pharmacological Society. Dec 2014;90c:88-115. Tanner GA, Tanner JA. Citrate therapy for polycystic kidney disease in rats. Kidney international. Nov 2000;58(5):1859-1869. Wackenfors A, Pantev E, Emilson M, Edvinsson L, Malmsjo M. Angiotensin II receptor mRNA expression and vasoconstriction in human coronary arteries: effects of heart failure and age. Basic & clinical pharmacology & toxicology. Dec 2004;95(6):266-272. Wagner E. Life Extension Magazine; In The News. Cystatin C Valuable in Detecting Kidney Dysfunction. http://www.lef.org//Magazine/2006/12/itn/Page-01. 2006. Accessed 1/27/2015. Watanabe H, Obata H, Watanabe T, Sasaki S, Nagai K, Aizawa Y. Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study. Diabetes/metabolism research and reviews. Jan 2010;26(1):26-32. Yadla M, Yanala SR, Parvithina S, Chennu KK, Annapindi N, Vishnubhotla S. Acute kidney injury in endosulfan poisoning. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. May 2013;24(3):592-593. Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Current molecular medicine. Aug 2007;7(5):463-469. Yao X, Panichpisal K, Kurtzman N, et al. Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007;334(2):115-24. Yokozawa T, Nakagawa T, Oya T, Okubo T, and Juneja LR. Green tea polyphenols and dietary fibre protect against kidney damage in rats with diabetic nephropathy. J. Pharm. Pharmacol. 2005;57(6):773–80 Younes N, Cleary PA, Steffes MW, de Boer IH, Molitch ME, Rutledge BN, . . . Dahms W. Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Clinical journal of the American Society of Nephrology : CJASN. Jul 2010;5(7):1235-1242. Yuzbashian E, Asghari G, Mirmiran P, Hosseini FS, Azizi F. Associations of dietary macronutrients with glomerular filtration rate and kidney dysfunction: Tehran lipid and glucose study. Journal of nephrology. Jun 5 2014. Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC nephrology. 2013;14:199. Zhu JR, Bai J, Cai NS, Tang B, Fan WH, Guo JZ, . . . Cheng NN. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. International journal of clinical practice. Supplement. Dec 2004(145):46-49. Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, . . . Mallamaci F. Paricalcitol and endothelial function in chronic kidney disease trial. Hypertension. Nov 2014;64(5):1005-1011. •••SUPPORT OUR SPONSORS••• (COACHING) Alex - www.theprepcoach.com (FREE OPEN FORUM w/ EXCLUSIVE VIDEOS) http://www.theprepcoachforum.com (SUPPLEMENTS) www.projectad.me___use discount code “BFR25” to save off your order! (RESEARCH CHEMS) www.maresearchchems.net___use discount code “alex15” to save off your order! (SPECIALTY SUPPS) www.masupps.com___use discount code “alex20” to save off your order! (INJECTABLE L-CARNITINE) www.synthetek.com___use discount code “alexkikel” to save off your order! (BULK SUPPLEMENTS) www.truenutrition.com___use discount code “AXK5” to save off your order! •••FIND THE EPISODES••• ITUNES:https://itunes.apple.com/us/podcast/beastfitness-radios-podcast/id1065532968 LIBSYN:http://beastfitnessradio.libsyn.com VIMEO: www.vimeo.com/theprepcoach •••PREP COACH APPAREL••• https://teespring.com/stores/the-prep-coach-apparel